CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Last trade$87.32
Day change-$0.02 (-0.02%)
Day range$86.45 – $88.57
Volume88,778
Market cap$4.40B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.4B
Price / earnings
36.19×
Price / book
10.21×
Price / sales
4.35×
EV / sales
4.08×
EV / EBITDA
21.12×
Profitability
Earnings per share
$2.41
Return on assets
17.03%
Return on equity
28.23%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.02×
Quick ratio
2.02×
Cash ratio
1.05×
Cash flow
Price / cash flow
26.63×
Price / free cash flow
34.39×
Free cash flow
$127.86M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CRVL, quarterly periods
Line item
Q2 FY2027 Sep 30, 2026
Q1 FY2027 Jun 30, 2026
Q4 FY2026 Mar 31, 2026
Q3 FY2026 Dec 31, 2025
Q2 FY2026 Sep 30, 2025
Q1 FY2026 Jun 30, 2025
Q4 FY2025 Mar 31, 2025
Q3 FY2025 Dec 31, 2024
Revenue
$267.13M
$259.93M
$248.55M
$235.63M
$239.64M
$234.71M
$231.51M
$227.97M
Cost of revenue
$194.83M
$192.13M
$185.54M
$180.71M
$181.47M
$177.95M
$173.33M
$175.12M
Gross profit
$72.3M
$67.79M
$63.01M
$54.92M
$58.18M
$56.76M
$58.18M
$52.86M
Selling, general and administrative
$26.45M
$24.45M
$23.29M
$22.68M
$22.28M
$21.48M
$24.86M
$22.06M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$26.45M
$24.45M
$23.29M
$22.68M
$22.28M
$21.48M
$24.86M
$22.06M
Operating income
$45.85M
$43.34M
$39.72M
$32.23M
$35.9M
$35.28M
$33.32M
$30.8M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$45.85M
$43.34M
$39.72M
$32.23M
$35.9M
$35.28M
$33.32M
$30.8M
Income taxes
$11.76M
$11.12M
$8.69M
$8.06M
$7.99M
$8.05M
$6.9M
$7.03M
Net income
$34.09M
$32.23M
$31.03M
$24.17M
$27.91M
$27.24M
$26.42M
$23.77M
Net income attributable to common shareholders
$34.09M
$32.23M
$31.03M
$24.17M
$27.91M
$27.24M
$26.42M
$23.77M
EBITDA
$55.03M
$52.1M
$47.98M
$40.3M
$43.74M
$42.87M
$40.92M
$38.3M
Basic earnings per share
$0.67
$0.63
$0.61
$0.47
$0.54
$0.53
$0.51
$0.46
Diluted earnings per share
$0.67
$0.63
$0.61
$0.47
$0.54
$0.52
$0.51
$0.46
Recent news
Company coverage with links to the original publishers.
CorVel reported Q4 2026 earnings with quarterly revenue of $249 million (7% YoY increase) and EPS of $0.61 (up 19.6%). Full-year revenue reached $959 million with EPS of $2.14 (17% increase). The company secured multiyear contracts with top national payers, achieved 56% YoY growth in new bookings, and expanded RFP activity by 20%. Network Solutions delivered double-digit growth while Patient Management showed low single-digit growth. Management emphasized investments in AI, automation, and platform integration to enhance scalability.
CorVel reported Q3 2026 results with modest growth: revenue of $236 million (up 3% YoY) and EPS of $0.47 (up 2% YoY). The company highlighted strong operational metrics including 100% net revenue retention, 44% new business close rate, and meaningful AI-driven efficiency gains. Management attributed the modest results to short-term operational factors and tax normalization rather than fundamental business changes. The CERES division showed strong momentum in healthcare payment integrity services, with accelerated technology integration from a June acquisition. CorVel maintains a strong balance sheet with $230 million in cash, no debt, and continues share repurchases.
CorVel reported Q2 2026 financial results with $240 million revenue, a 7% increase from the previous year. The company highlighted significant investments in Agentic AI technology, workforce development through CorVel University, and strategic efforts to address labor market challenges in workers' compensation.
CorVel Corporation announced a three-for-one forward stock split, effective December 24, 2024. The additional shares will be distributed on the same date, and trading is expected to begin on a post-split basis on December 26, 2024.
CORXEL, a biotech company, has acquired the worldwide (excluding Greater China) rights to CX11, an oral small molecule GLP-1 receptor agonist, for the treatment of obesity and diabetes. CX11 has shown promising results in a Phase 2 clinical trial conducted in China and CORXEL plans to initiate a global Phase 2 study in 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.